Pharmaceutical Executive
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Pharmaceutical Executive - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
2024 Pharm Exec Top 50 Companies
2024年6月14日 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in …
Publications - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
2023 Pharm Exec Top 50 Companies
2023年6月10日 · Movers and shakers. As mentioned, Pfizer and AbbVie captured the top two spots again in the Pharma 50—the latter, notably, expected to maintain its solid momentum, …
Global - PharmExec
2024年8月13日 · Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
About Us - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Pharmaceutical Executive: June 2024 - PharmExec
Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost …
Pharmaceutical Executive: July/August 2024 - PharmExec
2024年8月16日 · The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and …
Pharmaceutical Executive: November 2023 - PharmExec
2023年11月13日 · Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” …